Please login to the form below

Not currently logged in

Phase III trial for new cancer agent

Novartis AG announced on April 11 that phase III trials of a novel cancer agent, which could help over one million patients, have begun
Novartis AG announced on April 11 that phase III trials of a novel cancer agent, which could help over one million patients, have begun.

The US based pharmaceutical company has been developing ASA404 as a tumour-vascular disrupting agent (Tumour-VDA) to treat patients with non-small cell lung cancer (NSCLC). It reported positive results from phase III studies of ASA404 stating that it offered a survival advantage to patients of more than five months and it is hoped the agent will become a first-line treatment.

Alessandro Riva, executive vice-president and global head of development of Novartis oncology, said: "We look forward to exploring the unique mechanism of action of ASA404 in non-small lung cancer to potentially help the more than one million people who develop lung cancer each year."

The novel cancer agent causes extensive tumour cell death by collapsing blood supply to the cancerous growth area.

About 85 to 95 per cent of all diagnosed lung cancers are the NSCLC form of the disease. Globally, 1.2 million people are diagnosed with lung cancer every year, leading to 921,000 deaths.

Novartis says that ASA404 is one of six oncology compounds that are in development and hopes to register in the within five years.

David Epstein, president and CEO of Novartis oncology, said: "These exciting potential discoveries have the possibility to change medical treatment for patients suffering with many forms of cancer."

11th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....